Puma Biotechnology | PBYI - Trade Debtors


Puma Biotechnology reported $28.1M in Trade Debtors for its fiscal quarter ending in June of 2024.





Trade Debtors Change Date
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Alnylam Pharmaceuticals USD 883.96M 106.39M Mar/2026
Amgen USD 9.14B 432M Mar/2026
Biogen USD 1.79B 76.6M Mar/2026
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Daiichi Sankyo JPY 695.95B 79.1B Dec/2025
Esperion Therapeutics USD 140.19M 21.21M Dec/2025
Exelixis USD 328.95M 42.03M Mar/2026
Gilead Sciences USD 4.74B 172M Mar/2026
Glaxosmithkline GBP 10.49B 40.6M Mar/2026
Incyte USD 1.05B 27.09M Mar/2026
MacroGenics USD 10.42M 2.95M Mar/2026
Moderna USD 71M 113M Mar/2026
Novartis USD 9.6B 2.69B Mar/2026
Pfizer USD 16.17B 332M Mar/2026
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Regeneron Pharmaceuticals USD 5.73B 10.1M Mar/2026
Roche Holding CHF 11.9B 460M Dec/2025
Sangamo BioSciences USD 581K 110K Jun/2024
Sarepta Therapeutics USD 547.91M 149.68M Mar/2026
Takeda JPY 876.35B 118.43B Mar/2026
TG Therapeutics USD 392.05M 86.42M Mar/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024
Vertex Pharmaceuticals USD 2B 56.7M Mar/2026